COMPOSITIONS AND METHODS FOR COMBINATION ANTIVIRAL THERAPY
    2.
    发明申请
    COMPOSITIONS AND METHODS FOR COMBINATION ANTIVIRAL THERAPY 有权
    用于组合抗病毒治疗的组合物和方法

    公开(公告)号:US20090143314A1

    公开(公告)日:2009-06-04

    申请号:US12195161

    申请日:2008-08-20

    摘要: The present invention relates to therapeutic combinations of [2-(6-amino-purin-9-yl)-1-methyl-ethoxymethyl]-phosphonic acid diisopropoxycarbonyloxymethyl ester (tenofovir disoproxil fumarate, Viread®) and (2R, 5S, cis)-4-amino-5-fluoro-1-(2-hydroxymethyl-1,3-oxathiolan-5-yl)-(1H)-pyrimidin-2-one (emtricitabine, Emtriva™, (-)-cis FTC) and their physiologically functional derivatives. The combinations may be useful in the treatment of HIV infections, including infections with HIV mutants bearing resistance to nucleoside and/or non-nucleoside inhibitors. The present invention is also concerned with pharmaceutical compositions and formulations of said combinations of tenofovir disoproxil fumarate and emtricitabine, and their physiologically functional derivatives, as well as therapeutic methods of use of those compositions and formulations.

    摘要翻译: 本发明涉及[2-(6-氨基 - 嘌呤-9-基)-1-甲基 - 乙氧基甲基] - 膦酸二异丙氧基羰氧基甲酯(富马酸替诺福韦地索普洛尔,Viread)和(2R,5S, 顺式)-4-氨基-5-氟-1-(2-羟甲基-1,3-氧硫杂环戊烷-5-基) - (1H) - 嘧啶-2-酮(恩曲他滨,Emtriva TM,( - ) - 顺式FTC)及其生理功能衍生物。 这些组合可用于治疗HIV感染,包括具有对核苷和/或非核苷抑制剂的抗性的HIV突变体的感染。 本发明还涉及替诺福韦地索普西富马酸和恩曲他滨的组合的药物组合物和制剂及其生理功能衍生物,以及这些组合物和制剂的使用的治疗方法。

    Compositions and methods for combination antiviral therapy
    3.
    发明授权
    Compositions and methods for combination antiviral therapy 有权
    用于组合抗病毒治疗的组合物和方法

    公开(公告)号:US08716264B2

    公开(公告)日:2014-05-06

    申请号:US12204174

    申请日:2008-09-04

    IPC分类号: A61K31/675

    摘要: The present invention relates to therapeutic combinations of [2-(6-amino-purin-9-yl)-1-methyl-ethoxymethyl]-phosphonic acid diisopropoxycarbonyloxymethyl ester (tenofovir disoproxil fumarate, Viread®) and (2R,5S,cis)-4-amino-5-fluoro-1-(2-hydroxymethyl-1,3-oxathiolan-5-yl)-(1H)-pyrimidin-2-one (emtricitabine, Emtriva™, (−)-cis FTC) and their physiologically functional derivatives. The combinations may be useful in the treatment of HIV infections, including infections with HIV mutants bearing resistance to nucleoside and/or non-nucleoside inhibitors. The present invention is also concerned with pharmaceutical compositions and formulations of said combinations of tenofovir disoproxil fumarate and emtricitabine, and their physiologically functional derivatives, as well as therapeutic methods of use of those compositions and formulations.

    摘要翻译: 本发明涉及[2-(6-氨基 - 嘌呤-9-基)-1-甲基 - 乙氧基甲基] - 膦酸二异丙氧基羰基氧基甲酯(富马酸替诺福韦地索普洛尔,Viread)和(2R,5S,顺式) -4-氨基-5-氟-1-(2-羟甲基-1,3-氧硫杂环戊烷-5-基) - (1H) - 嘧啶-2-酮(恩曲他滨,Emtriva TM,( - ) - 顺式FTC)和 其生理功能衍生物。 这些组合可用于治疗HIV感染,包括具有对核苷和/或非核苷抑制剂的抗性的HIV突变体的感染。 本发明还涉及替诺福韦地索普西富马酸和恩曲他滨的组合的药物组合物和制剂及其生理功能衍生物,以及这些组合物和制剂的使用的治疗方法。

    Compositions and methods for combination antiviral therapy
    4.
    发明授权
    Compositions and methods for combination antiviral therapy 有权
    用于组合抗病毒治疗的组合物和方法

    公开(公告)号:US08592397B2

    公开(公告)日:2013-11-26

    申请号:US12195161

    申请日:2008-08-20

    IPC分类号: A61K31/675

    摘要: The present invention relates to therapeutic combinations of [2-(6-amino-purin-9-yl)-1-methyl-ethoxymethyl]-phosphonic acid diisopropoxycarbonyloxymethyl ester (tenofovir disoproxil fumarate, Viread®) and (2R, 5S, cis)-4-amino-5-fluoro-1-(2-hydroxymethyl-1,3-oxathiolan-5-yl)-(1H)-pyrimidin-2-one(emtricitabine, Emtriva™, (-)-cis FTC) and their physiologically functional derivatives. The combinations may be useful in the treatment of HIV infections, including infections with HIV mutants bearing resistance to nucleoside and/or non-nucleoside inhibitors. The present invention is also concerned with pharmaceutical compositions and formulations of said combinations of tenofovir disoproxil fumarate and emtricitabine, and their physiologically functional derivatives, as well as therapeutic methods of use of those compositions and formulations.

    摘要翻译: 本发明涉及[2-(6-氨基 - 嘌呤-9-基)-1-甲基 - 乙氧基甲基] - 膦酸二异丙氧基羰基氧基甲酯(富马酸替诺福韦地索普洛尔,Viread)和(2R,5S,顺式) -4-氨基-5-氟-1-(2-羟甲基-1,3-氧硫杂环戊烷-5-基) - (1H) - 嘧啶-2-酮(恩曲他滨,Emtriva TM,( - ) - 顺式FTC )及其生理功能衍生物。 这些组合可用于治疗HIV感染,包括具有对核苷和/或非核苷抑制剂的抗性的HIV突变体的感染。 本发明还涉及替诺福韦地索普西富马酸和恩曲他滨的组合的药物组合物和制剂及其生理功能衍生物,以及这些组合物和制剂的使用的治疗方法。

    COMPOSITIONS AND METHODS FOR COMBINATION ANTIVIRAL THERAPY
    5.
    发明申请
    COMPOSITIONS AND METHODS FOR COMBINATION ANTIVIRAL THERAPY 有权
    用于组合抗病毒治疗的组合物和方法

    公开(公告)号:US20090036408A1

    公开(公告)日:2009-02-05

    申请号:US12204174

    申请日:2008-09-04

    摘要: The present invention relates to therapeutic combinations of [2-(6-amino-purin-9-yl)-1-methyl-ethoxymethyl]-phosphonic acid diisopropoxycarbonyloxymethyl ester (tenofovir disoproxil fumarate, Viread®) and (2R,5S, cis)-4-amino-5-fluoro-1-(2-hydroxymethyl-1,3-oxathiolan-5-yl)-(1H)-pyrimidin-2-one (emtricitabine, Emtriva™, (−)-cis FTC) and their physiologically functional derivatives. The combinations may be useful in the treatment of HIV infections, including infections with HIV mutants bearing resistance to nucleoside and/or non-nucleoside inhibitors. The present invention is also concerned with pharmaceutical compositions and formulations of said combinations of tenofovir disoproxil fumarate and emtricitabine, and their physiologically functional derivatives, as well as therapeutic methods of use of those compositions and formulations.

    摘要翻译: 本发明涉及[2-(6-氨基 - 嘌呤-9-基)-1-甲基 - 乙氧基甲基] - 膦酸二异丙氧羰基氧基甲酯(富马酸替诺福韦地索普洛尔,Viread)和(2R,5S, 顺式)-4-氨基-5-氟-1-(2-羟甲基-1,3-氧硫杂环戊烷-5-基) - (1H) - 嘧啶-2-酮(恩曲他滨,Emtriva TM,( - ) - 顺式FTC)及其生理功能衍生物。 这些组合可用于治疗HIV感染,包括具有对核苷和/或非核苷抑制剂的抗性的HIV突变体的感染。 本发明还涉及替诺福韦地索普西富马酸和恩曲他滨的组合的药物组合物和制剂及其生理功能衍生物,以及这些组合物和制剂的使用的治疗方法。